The firm's microfluidic-based technology collects and purifies genetic material, causing a complete PCR reaction that identifies diseases in liquid samples.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
The firm will begin initial trials for antibiotic-resistant urinary tract infection detection in UK hospitals in early 2018.
The firm plans to expedite cell sorting for research labs with an inexpensive device that uses piezoelectric actuators and disposable microfluidics.
The SBIR grant will support the development of the firm's single-cell analysis platform, Tapestri.
The firm's microfluidic based technology collects and purifies genetic material, producing a complete PCR reaction to identify pathogens in liquid samples.
The firm will use the proceeds to develop its cell-sorting technology for cell line development, genomic sample preparation, CRISPR gene editing, and antibody discovery.
Hangzhou Chengyuan Genomics will provide single-cell analysis services and sell 1CellBio's InDrop instrument, reagents, and kits in China.
The system uses microfluidics and real-time image analysis to isolate single cells and provide visual documentation of monoclonality.
The device allows researchers to track cancer growth for a longer period of time, enabling improved observations and analysis, according to the researchers.
The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.
Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.
A Washington Post columnist writes that she is skeptical about DNA-based diets.
In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.